CAR - t细胞疗法和双特异性抗体治疗复发/难治性大b细胞淋巴瘤。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI:10.11406/rinketsu.66.432

Hideki Goto

{"title":"CAR - t细胞疗法和双特异性抗体治疗复发/难治性大b细胞淋巴瘤。","authors":"Hideki Goto","doi":"10.11406/rinketsu.66.432","DOIUrl":null,"url":null,"abstract":"While many cases of large B-cell lymphoma (LBCL) can be cured with initial treatment, some patients experience relapse or are refractory to treatment. Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies can be used for relapsed or chemotherapy-refractory LBCL. This review highlights the latest evidence regarding CAR T-cell therapy and bispecific antibodies for relapsed or refractory LBCL.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 6","pages":"432-439"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[CAR T-cell therapy and bispecific antibodies for relapsed/refractory large B-cell lymphoma].\",\"authors\":\"Hideki Goto\",\"doi\":\"10.11406/rinketsu.66.432\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"While many cases of large B-cell lymphoma (LBCL) can be cured with initial treatment, some patients experience relapse or are refractory to treatment. Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies can be used for relapsed or chemotherapy-refractory LBCL. This review highlights the latest evidence regarding CAR T-cell therapy and bispecific antibodies for relapsed or refractory LBCL.\",\"PeriodicalId\":93844,\"journal\":{\"name\":\"[Rinsho ketsueki] The Japanese journal of clinical hematology\",\"volume\":\"66 6\",\"pages\":\"432-439\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"[Rinsho ketsueki] The Japanese journal of clinical hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11406/rinketsu.66.432\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Rinsho ketsueki] The Japanese journal of clinical hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11406/rinketsu.66.432","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

虽然许多大b细胞淋巴瘤（LBCL）可以通过初始治疗治愈，但有些患者会复发或难以治疗。嵌合抗原受体（CAR） t细胞疗法和双特异性抗体可用于复发或化疗难治性LBCL。这篇综述强调了CAR - t细胞疗法和双特异性抗体治疗复发或难治性LBCL的最新证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[CAR T-cell therapy and bispecific antibodies for relapsed/refractory large B-cell lymphoma].

While many cases of large B-cell lymphoma (LBCL) can be cured with initial treatment, some patients experience relapse or are refractory to treatment. Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies can be used for relapsed or chemotherapy-refractory LBCL. This review highlights the latest evidence regarding CAR T-cell therapy and bispecific antibodies for relapsed or refractory LBCL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

[Rinsho ketsueki] The Japanese journal of clinical hematology

自引率

0.00%

发文量